Development of HeartLander as an epicardial injection delivery system

描述(由申请者提供)：许多必须进入心壁的创新疗法现在正在开发中。这些疗法通常需要精确放置可注射物质的精确量度，并旨在通过微创方式提供，以将患者创伤降至最低。不幸的是，提供这种治疗的传统方法，如冠状动脉内和心内膜导管和柔性内窥镜，已被证明是不够的。到目前为止，心脏外膜给药系统已在其研究成果中显示出解决这一问题的巨大潜力。这项拟议的努力将采用哈特兰德研究原型，并通过为其提供所需的功能和安全能力来将其翻译为适合于满足临床需求。 与公共卫生相关：通过开发具有所需的临床和安全特性的心脏外膜给药系统，允许以对患者最小的侵入性可靠地将大量创新疗法注入心壁，一系列令人烦恼的心脏疾病将是可治疗的，而这些疾病目前并未得到很好的处理。

DESCRIPTION (provided by applicant): Numerous innovative therapies that must be delivered into the heart wall are now under development. These therapies typically require precise placement of a precise measure of an injectable substance and are intended to be delivered by minimally invasive means to minimize patient trauma. Unfortunately, traditional approaches for delivering such therapies, such as intracoronary and endocardial catheters and flexible endoscopy, have proven insufficient. The HeartLander epicardial delivery system has shown great potential for addressing this issue in its research outcomes to date. This proposed effort will take the HeartLander research prototype and translate it to be appropriate for meeting clinical needs by providing it with needed functional and safety capabilities. PUBLIC HEALTH RELEVANCE: By developing the HeartLander epicardial delivery system to have the needed clinical and safety characteristics to allow a host of innovative therapies to be reliably injected into the heart wall with minimal invasiveness to the patient, a spectrum of vexing cardiac conditions will be treatable that are now not well handled.